Last reviewed · How we verify
tezepelumab (Arm1&Arm2)
Tezepelumab blocks the activity of thymic stromal lymphopoietin (TSLP), a key cytokine involved in allergic inflammation.
Tezepelumab blocks the activity of thymic stromal lymphopoietin (TSLP), a key cytokine involved in allergic inflammation. Used for Severe asthma with an eosinophilic phenotype, Eosinophilic granulomatosis with polyangiitis (EGPA).
At a glance
| Generic name | tezepelumab (Arm1&Arm2) |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | Monoclonal antibody |
| Target | Thymic stromal lymphopoietin (TSLP) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting TSLP, tezepelumab prevents the activation of immune cells that contribute to the inflammatory response, thereby reducing symptoms associated with allergic diseases such as asthma.
Approved indications
- Severe asthma with an eosinophilic phenotype
- Eosinophilic granulomatosis with polyangiitis (EGPA)
Common side effects
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tezepelumab (Arm1&Arm2) CI brief — competitive landscape report
- tezepelumab (Arm1&Arm2) updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI